These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 10794098)

  • 1. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates.
    Corash L
    Dev Biol (Basel); 2000; 102():115-23. PubMed ID: 10794098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates.
    Corash L
    Vox Sang; 2000; 78 Suppl 2():205-10. PubMed ID: 10938954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
    Corash L
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates.
    Corash L
    Vox Sang; 1998; 74 Suppl 2():173-6. PubMed ID: 9704443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of infectious pathogens in labile blood components: meeting the challenge.
    Corash L
    Transfus Clin Biol; 2001 Jun; 8(3):138-45. PubMed ID: 11499954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen reduction technology: methods, status of clinical trials, and future prospects.
    Corash L
    Curr Hematol Rep; 2003 Nov; 2(6):495-502. PubMed ID: 14561394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing the risk of bacterial contamination of cellular blood components.
    Blajchman MA
    Dev Biol (Basel); 2000; 102():183-93. PubMed ID: 10794105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The virucidal effect of platelet concentrates: preliminary study and first conclusions.
    Maurice A; Marchand-Arvier M; Edert D; Le Faou A; Gondrexon G; Vigneron C
    Platelets; 2002 Jun; 13(4):219-22. PubMed ID: 12189023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogen inactivation technology: cleansing the blood supply.
    Klein HG
    J Intern Med; 2005 Mar; 257(3):224-37. PubMed ID: 15715679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of viruses in red cell and platelet concentrates with aluminum phthalocyanine (AIPc) sulfonates.
    Horowitz B; Rywkin S; Margolis-Nunno H; Williams B; Geacintov N; Prince AM; Pascual D; Ragno G; Valeri CR; Huima-Byron T
    Blood Cells; 1992; 18(1):141-9; discussion 150. PubMed ID: 1617188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC 4 and red light.
    Ben-Hur E; Chan WS; Yim Z; Zuk MM; Dayal V; Roth N; Heldman E; Lazo A; Valeri CR; Horowitz B
    Dev Biol (Basel); 2000; 102():149-55. PubMed ID: 10794102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates.
    Terpstra FG; van 't Wout AB; Schuitemaker H; van Engelenburg FA; Dekkers DW; Verhaar R; de Korte D; Verhoeven AJ
    Transfusion; 2008 Feb; 48(2):304-13. PubMed ID: 18028277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light.
    Ruane PH; Edrich R; Gampp D; Keil SD; Leonard RL; Goodrich RP
    Transfusion; 2004 Jun; 44(6):877-85. PubMed ID: 15157255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)-photoinactivation.
    Trannoy LL; Terpstra FG; de Korte D; Lagerberg JW; Verhoeven AJ; Brand A; van Engelenburg FA
    Vox Sang; 2006 Aug; 91(2):111-8. PubMed ID: 16907871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bacterial contamination: should it be detected or inactivated?].
    Cazenave JP
    Transfus Clin Biol; 2007 May; 14(1):81-5. PubMed ID: 17521943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in improving the pathogen safety of red cell concentrates.
    Chapman J
    Vox Sang; 2000; 78 Suppl 2():203-4. PubMed ID: 10938953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
    Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
    Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
    Blajchman MA
    Transfus Clin Biol; 2009 May; 16(2):70-4. PubMed ID: 19427252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.